National Psoriasis Foundation backs bill to lower treatment costs
In response to the rising cost of treating psoriasis and psoriatic arthritis, the National Psoriasis Foundation (NPF) has teamed with 32 other patient advocacy and medical organizations to help ensure treatments for lifelong, chronic diseases remain accessible. The Coalition for Accessible Treatments is working with concerned members of Congress to build support for the bipartisan Patients' Access to Treatments Act (PATA), introduced by Rep. David McKinley (R-W.V.) and Rep. Lois Capps (D-Calif.).
How the bill would work
PATA urges Congress to address the increasing out-of-pocket costs for prescription drugs. If passed, this bill will:
- Limit your co-payments and out-of-pocket expenses on your biologics and other specialty medications.
- Eliminate financial barriers to ensure you have access to the medication your doctor prescribes.
PATA will provide vital assistance to many Americans living with psoriatic disease and other chronic diseases.
Cost a burden for patients
A recent study co-authored by Dr. April Armstrong of the National Psoriasis Foundation Medical Board found that the economic burden of psoriasis is up to $135 billion per year. The study, published in JAMA Dermatology, found the direct costs of psoriasis – including doctor's appointments and treatments – could be upwards of $8,000 annually.